drugset / Trial / NCT07591090
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-09-01
- Completion
- 2029-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK146D1 | Unknown | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |